Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ritlecitinib in children aged 6 to under 12 years with severe alopecia areata
jRCT2031250283Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in alopecia areata (3 arms), sponsored by Pfizer. Primary endpoints: Absolute SALT score <=20 response at Week 24 and Absolute SALT score <=10 response at Week 24. Started Sep 2025; status: active, not recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2031250283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250283.